Assessment of metabolic risk factors in patients undergoing antipsychotic drug therapy: A Pharmacist-led study

[1]  Sharad Chand,et al.  Association Between Metabolic Syndrome and Diabetes Mellitus According to International Diabetic Federation and National Cholesterol Education Program Adult Treatment Panel III Criteria: a Cross-sectional Study , 2020, Journal of Diabetes & Metabolic Disorders.

[2]  V. Raj,et al.  A Comparative Study on Relative Safety and Efficacy of Chlorpromazine and Risperidone in Schizophrenia patients , 2020 .

[3]  K. Aihara,et al.  Interactions between CKD and MetS and the Development of CVD , 2011, Cardiology research and practice.

[4]  T. Schwartz,et al.  Weight Gain, Obesity, and Psychotropic Prescribing , 2011, Journal of obesity.

[5]  R. Ries,et al.  Metabolic risk factors among medicaid outpatients with schizophrenia receiving second-generation antipsychotics. , 2009, Psychiatric services.

[6]  A. Serretti,et al.  Weight gain in antipsychotic-naive patients: a review and meta-analysis , 2009, Psychological Medicine.

[7]  N. Manjunatha,et al.  Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study. , 2007, The Journal of clinical psychiatry.

[8]  Heiner Boeing,et al.  Comparison of Anthropometric Characteristics in Predicting the Incidence of Type 2 Diabetes in the EPIC-Potsdam Study A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances. , 2006, Diabetes Care.

[9]  J. Lieberman,et al.  Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III , 2005, Schizophrenia Research.

[10]  Gro Harlem Brundtland,et al.  Mental Health: New Understanding, New Hope , 2001 .

[11]  J. Raniwalla,et al.  Quetiapine: a review of its safety in the management of schizophrenia. , 2000, Drug safety.

[12]  M. Heo,et al.  Antipsychotic-induced weight gain: a comprehensive research synthesis. , 1999, The American journal of psychiatry.

[13]  A. Alao,et al.  Isoniazid-Induced Psychosis , 1998, The Annals of pharmacotherapy.

[14]  R. Leadbetter,et al.  Clozapine-induced weight gain: prevalence and clinical relevance. , 1992, The American journal of psychiatry.